ArticleJournal of thoracic disease2025
Clinicopathological characteristics and prognosis analysis of stage IB non-small cell lung cancer-a retrospective study from a Chinese medical center.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Significant improvement in overall survival with postoperative traditional Chinese medicine in stage I lung adenocarcinoma: a real-world retrospective cohort study.Translational lung cancer research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognosis of stage IB non-small cell lung cancer (NSCLC) is not satisfactory, and studies on stage IB NSCLC remain lacking. The study aimed to investigate the clinicopathological characteristics and prognostic factors of patients with stage IB NSCLC, and to provide new evidence for clinical management. Methods: A total of 971 NSCLC patients with pathological stage IB who were resected by surgery (R0) from January 2016 to December 2020 were reviewed. The primary endpoint was disease-free survival (DFS) and the secondary endpoint was overall survival (OS). The baseline characteristics of the patients were obtained statistically, and factors affecting the prognosis were analyzed using survival analysis and Cox proportional hazard models. Results: There was no statistical difference in DFS (P=0.48) and OS (P=0.24) between lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Univariate analysis for OS revealed that age, smoking status, lymphovascular invasion, pleural invasion, ground-glass opacity (GGO) component, spread through air spaces (STAS), EGFR mutations, and micropapillary component but not postoperative adjuvant therapy were strongly associated with patient survival in stage IB NSCLC. Multivariate analysis for OS revealed that pleural invasion [hazard ratio (HR) =6.72, P=0.01], STAS (HR =6.72, P<0.001), and GGO component (HR =0.18, P<0.001) were independent risk factors in stage IB LUAD, while STAS (HR =18.0, P=0.007) in stage IB LUSC. The STAS(+)/GGO(-) group had a significantly worse prognosis, with shorter DFS and OS than the other three groups (P<0.001) in stage IB LUAD. Conclusions: Major pathologic type was not a risk factor for stage IB NSCLC. Postoperative adjuvant therapy did not benefit patients with stage IB NSCLC. In stage IB LUAD, pleural invasion, presence of STAS, and absence of GGO were independent risk factors. In stage IB LUSC, having STAS was an independent risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.